ROIV at a glance
The past year
Chart+89.9% $38.96, close Nov 19
- From the highest close
- −6.9%
- Vs the 200-day average
- +19.3%
Short interest
History45.5M shares
- Of shares outstanding
- 6.28%
- Since the last report
- +12.9%
- Days to cover
- 6.1 days
- Settled
- Oct 30, 2026
Congress and officials
TradesNone in 90 days
- Disclosed trades on record
- 4
Insider buying, 7 days
FilingsNone filed this week
- Form 4s filed
- Nov 14 – Nov 20
Top investors
Funds2 of 37 funds hold it
- Andreas Halvorsen
- 0.8%
- Maverick Capital
- 0.7%
- Latest 13F filings
- 1 added · 1 cut
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
ROIV price history
Loading ROIV and S&P 500 price history…
Loading recent earnings…
Investment thesis
What must happen next
Roivant’s platform must keep producing externally validated drug assets, so value creation comes from repeatable partnerships, sales, approvals, or launch paths rather than from one exceptional past transaction.HoldingMateriality: High
FY2024 annual GAAP operating_income was positive $4.497 billion, showing that a single successful asset monetization can create very large reported value. If this holds, losses are investments in future option value; if it breaks, the equity becomes a wasting pool of cash funding uncertain R&D.
Watch: Large pharmaceutical buyers stop paying strategic premiums for Roivant-originated or Roivant-developed assets after clinical diligence.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
FY2024 annual GAAP operating_income was positive $4.497 billion, showing that a single successful asset monetization can create very large reported.
Open source ↗Roivant’s large cash balance gives management time to fund clinical milestones without being forced into unfavorable financing, but that advantage only persists if burn is actively managed.StrengtheningMateriality: High
Cash was $1.419 billion at March 31, 2026. Cash runway determines whether shareholders own the pipeline upside or get diluted before the key readouts arrive.
Watch: Management commits to multiple large late-stage trials or acquisitions before existing programs generate partner funding.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Cash was $1.419 billion at March 31, 2026.
Open source ↗Roivant’s value must come from pipeline progression and strategic validation, because the current business has not yet demonstrated a self-funding commercial revenue engine.WeakeningMateriality: Medium
FY2026 annual GAAP revenue was $8.26 million, down from $29.1 million in FY2025 and $32.7 million in FY2024. Owners should judge the company by clinical and business-development milestones, not by near-term sales growth; if no commercial engine emerges, terminal value depends on exits rather than durable earnings.
Watch: Roivant fails to advance any program toward approval or commercialization while revenue remains immaterial.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
FY2026 annual GAAP revenue was $8.26 million, down from $29.1 million in FY2025 and $32.7 million in FY2024.
Open source ↗The platform only compounds per-share value if Roivant cuts, sells, or partners programs that do not clear a high bar instead of funding every asset through expensive development.HoldingMateriality: Medium
FY2026 annual GAAP operating_cash_flow was negative $750.3 million, a slightly smaller cash use than negative $839.5 million in FY2025. Disciplined capital allocation turns cash into asymmetric pipeline options; weak discipline turns the same cash into recurring losses.
Watch: Roivant starts additional capital-intensive late-stage programs without partner funding or clear prioritization.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
FY2026 annual GAAP operating_cash_flow was negative $750.3 million, a slightly smaller cash use than negative $839.5 million in FY2025.
Open source ↗Roivant’s ability to accelerate medicines depends on maintaining enough specialized clinical, regulatory, and commercial talent inside the parent and subsidiaries to run multiple focused programs effectively.HoldingMateriality: Medium
Roivant and its subsidiaries had approximately 721 full-time employees as of March 31, 2026. The platform structure has value only if its people can execute faster and better than a conventional biotech holding company.
Watch: Senior scientific, clinical, or regulatory leaders leave key subsidiaries before important trial or regulatory milestones.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Roivant and its subsidiaries had approximately 721 full-time employees as of March 31, 2026.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Roivant’s platform must keep producing externally validated drug assets, so value creation comes from repeatable partnerships, sales, approvals, or launch paths rather than from one exceptional past transaction. If this holds, losses are investments in future option value; if it breaks, the equity becomes a wasting pool of cash funding uncertain R&D.
Roivant’s large cash balance gives management time to fund clinical milestones without being forced into unfavorable financing, but that advantage only persists if burn is actively managed. Cash runway determines whether shareholders own the pipeline upside or get diluted before the key readouts arrive.
Roivant’s value must come from pipeline progression and strategic validation, because the current business has not yet demonstrated a self-funding commercial revenue engine. Owners should judge the company by clinical and business-development milestones, not by near-term sales growth; if no commercial engine emerges, terminal value depends on exits rather than durable earnings.
The platform only compounds per-share value if Roivant cuts, sells, or partners programs that do not clear a high bar instead of funding every asset through expensive development. Disciplined capital allocation turns cash into asymmetric pipeline options; weak discipline turns the same cash into recurring losses.
Roivant’s ability to accelerate medicines depends on maintaining enough specialized clinical, regulatory, and commercial talent inside the parent and subsidiaries to run multiple focused programs effectively. The platform structure has value only if its people can execute faster and better than a conventional biotech holding company.
All standing thesis claims
Original report summary
its “vant” model repeatedly turns clinical development assets into approvals, partnerships, or sales before cash burn erodes the optionality.
Bull case and bear case
Bull case and bear case for Roivant Sciences
Where the evidence on Roivant Sciences disagrees: Mixed on the latest evidence (Oct 15, 2026). Of its 5 thesis points, 1 strengthening, 3 holding and 1 weakening.
Bull case: what the evidence supports
Roivant’s platform must keep producing externally validated drug assets, so value creation comes from repeatable partnerships, sales, approvals, or launch paths rather than from one exceptional past transaction.
Roivant’s large cash balance gives management time to fund clinical milestones without being forced into unfavorable financing, but that advantage only persists if burn is actively managed.
The platform only compounds per-share value if Roivant cuts, sells, or partners programs that do not clear a high bar instead of funding every asset through expensive development.
Roivant’s ability to accelerate medicines depends on maintaining enough specialized clinical, regulatory, and commercial talent inside the parent and subsidiaries to run multiple focused programs effectively.
Bear case: what the evidence questions
Roivant’s value must come from pipeline progression and strategic validation, because the current business has not yet demonstrated a self-funding commercial revenue engine.
Thesis-Break Engine
What has broken in Roivant Sciences’s thesis
Each break OptimistFi flagged on Roivant Sciences, dated — with what has historically followed the same kind of break across the market, not a forecast for Roivant Sciences.
- Analyst downgradecondition set before this filing
Across all companies, this kind of break has happened 12,641 times before. Those stocks trailed comparable companies by a median of 1% over the next six months, and 33% of them trailed it by 10 points or more.
- Insider-selling clustercondition set before this filing
Across all companies, this kind of break has happened 9,137 times before. Those stocks beat comparable companies by a median of 1% over the next six months, and 30% of them trailed it by 10 points or more.
- Price target fell below the stockcondition set before this filing
Across all companies, this kind of break has happened 1,809 times before. Those stocks trailed comparable companies by a median of 1% over the next six months, and 33% of them trailed it by 10 points or more.
Several kinds of break have stacked on Roivant Sciences at once. A cluster is a stronger read than any one signal alone.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedRegulation FD disclosure.
Roivant Sciences filed an SEC 8-K on 2026-09-08: Regulation FD disclosure. It is a dated development that tests the current thesis.
- MixedOther material event.
Roivant Sciences filed an SEC 8-K on 2026-08-28: Other material event. It is a dated development that tests the current thesis.
- MixedRegulation FD disclosure.
Roivant Sciences filed an SEC 8-K on 2026-08-27: Regulation FD disclosure. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Large pharmaceutical buyers stop paying strategic premiums for Roivant-originated or Roivant-developed assets after clinical diligence.
- Management commits to multiple large late-stage trials or acquisitions before existing programs generate partner funding.
- Roivant fails to advance any program toward approval or commercialization while revenue remains immaterial.
- Roivant starts additional capital-intensive late-stage programs without partner funding or clear prioritization.
- Senior scientific, clinical, or regulatory leaders leave key subsidiaries before important trial or regulatory milestones.
ROIV news
Loading headlines…
Financial statements
ROIV income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
ROIV: quick answers
- When does Roivant Sciences (ROIV) report earnings next?
- Roivant Sciences's next results are projected for February 5, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 9, 2026. Earnings calendar
- What is ROIV's short interest?
- As of October 30, 2026, 45.5M ROIV shares were sold short, 6.28% of its shares outstanding, up 12.9% from the count before. At the stock's average daily volume that is 6.1 days to cover. FINRA publishes the count twice a month. ROIV short interest history
- Have members of Congress traded ROIV?
- 4 trades in ROIV have been disclosed under the STOCK Act by members of Congress, the President or senior officials, none in reports made public in the last 90 days. Every disclosed ROIV trade
- Which well-known investors own ROIV?
- 2 of the 37 well-known funds tracked here reported ROIV shares in their latest 13F filings. By share of the fund's portfolio: Viking Global Investors (Andreas Halvorsen), 0.8%; Maverick Capital, 0.7%. Fund portfolios
ROIV in well-known investors’ portfolios
2 of 37 funds reported ROIV shares in their latest 13F filing. A 13F shows quarter-end positions and arrives up to 45 days later.
| Fund | Of its portfolio | Value | Change | Quarter |
|---|---|---|---|---|
| Andreas HalvorsenViking Global Investors | 0.76% | $247M | +7.8% | Q3 2026 |
| Maverick Capital | 0.66% | $84.4M | −18.4% | Q3 2026 |

